Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

77 results about "Cyclic oligosaccharide" patented technology

Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof

InactiveUS20130209558A1Improve stabilitySuperior dissolution profileBiocideHeavy metal active ingredientsDiseaseOral treatment
In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5, and wherein the pharmaceutically acceptable excipient is either a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide or a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. The invention moreover relates to the above pharmaceutical composition for the above use wherein the dosage regimen comprises at least the administration of a dose of 100 to 600 mg/m2/per person of bendamustine on day 1 and day 2, optionally a dose of 50 to 150 mg/m2 i.v. or orally of a corticosteroid on days 1 to 5, and optionally a suitable dose of a further active agent selected from the group consisting of an antibody specific for CD20, an anthracyclin derivative, a vinca alkaloid or a platin derivative; and the repetition of said dosage regimen 4 to 15 times after intervals of two to four weeks.
Owner:ASTELLAS DEUTLAND

Methods of fragrancing a surface

The present invention provides a method of applying a fragrance to a surface such as skin and/or hair. The method comprises applying to one area of the surface a first composition wherein the first composition comprises at least one first fragrance oil; at least one first cyclic oligosaccharide, wherein the at least one first fragrance oil and the at least one first cyclic oligosaccharide form a complex, which complex is dissolved or dispersed in the first composition; and a first solvent or a mixture thereof, wherein the first solvent or the mixture thereof has a dielectric constant at 25° C. of greater than or equal to 43, preferably greater than or equal to 45. The method also comprises simultaneously or sequentially, in either order, applying to the one area or an area adjacent thereto a second composition wherein the second composition comprises at least one second fragrance oil; and a second solvent, or a mixture thereof, wherein the at least one second fragrance oil is soluble or is dispersed at 25° C. in the second solvent or mixture thereof. The invention also provides a delivery package and a kit suitable for use in the above-mentioned method of applying a fragrance to a surface. The invention facilitates the achievement of unique lasting fragrance character combinations arising from the combination of the individual fragrance character profiles of the first and second compositions.
Owner:THE PROCTER & GAMBLE COMPANY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products